Oral Insulin Secretagogues, Insulin, and Cancer Risk in Type 2 Diabetes Mellitus

Chia-Hsuin Chang; Jou-Wei Lin; Li-Chiu Wu; Mei-Shu Lai; Lee-Ming Chuang

首页> 外文期刊>The journal of clinical endocrinology and metabolism >Oral Insulin Secretagogues, Insulin, and Cancer Risk in Type 2 Diabetes Mellitus

【24h】

Oral Insulin Secretagogues, Insulin, and Cancer Risk in Type 2 Diabetes Mellitus

机译：2型糖尿病的口服胰岛素促分泌剂，胰岛素和癌症风险

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:Hyperinsulinemia might be the mechanism leading to an increased cancer risk in patients with type 2 diabetes. The objective was to evaluate the association between oral insulin secretagogues, insulins, and cancer incidence.

机译：背景：高胰岛素血症可能是导致2型糖尿病患者癌症风险增加的机制。目的是评估口服胰岛素促泌剂，胰岛素与癌症发生率之间的关联。

著录项

来源
《The journal of clinical endocrinology and metabolism》 |2012年第7期|共6页
作者
Chia-Hsuin Chang; Jou-Wei Lin; Li-Chiu Wu; Mei-Shu Lai; Lee-Ming Chuang;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus. [J] . Yamada S, Watanabe M, Funae O, Internal medicine. . 2007,第23期

机译：速效胰岛素促分泌素（格列奈特）与预混胰岛素在2型糖尿病中的联合治疗效果。
2. Impact of diet on the efficacy of insulin lispro mix 25 and insulin lispro mix 50 as starter insulin in East Asian patients with type 2 diabetes: Subgroup analysis of the Comparison Between Low Mixed Insulin and Mid Mixed Insulin as Starter Insulin For Patients with Type 2 Diabetes Mellitus (CLASSIFY Study) randomized trial [J] . Chen Wei, Qian Lei, Watada Hirotaka, Journal of diabetes investigation. . 2017,第1期

机译：饮食对东亚2型糖尿病患者使用lispro mix 25和lispro mix 50作为起始胰岛素的功效的影响：低混合胰岛素和中度混合胰岛素作为2型糖尿病患者的起始胰岛素比较的亚组分析Mellitus（CLASSIFY研究）随机试验
3. Impact of diet on the efficacy of insulin lispro mix 25 and insulin lispro mix 50 as starter insulin in East Asian patients with type 2 diabetes: Subgroup analysis of the Comparison Between Low Mixed Insulin and Mid Mixed Insulin as Starter Insulin For Patients with Type 2 Diabetes Mellitus (CLASSIFY Study) randomized trial [J] . Chen Wei, Qian Lei, Watada Hirotaka, Journal of diabetes investigation. . 2017,第1期

机译：饮食对东亚2型糖尿病患者使用lispro mix 25和lispro mix 50作为起始胰岛素的功效的影响：低混合胰岛素和中度混合胰岛素作为2型糖尿病患者的起始胰岛素比较的亚组分析Mellitus（CLASSIFY研究）随机试验
4. Insulin-Coenzyme Q_(10) coencapsulated PLGA nanoparticles for oral delivery: A better regimen for treatment of diabetes mellitus and its complications [C] . G. Sharma, D. V. Ratnam, G. Mittal, Controlled Release Society Annual Meeting and Exposition . 2007

机译：胰岛素-辅酶Q_（10）共包封的口服PLGA纳米颗粒：治疗糖尿病及其并发症的更好方案
5. Modeling of the insulin pathway in insulin therapy to improve normoglycemic control of patients wtih type 1 diabetes mellitus [D] . Chan, Alice 2011

机译：胰岛素治疗中胰岛素途径的建模以改善1型糖尿病患者的正常血糖控制
6. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus [O] . Bianca Hemmingsen, David Peick Sonne, Maria‐Inti Metzendorf, -1

机译：预防或延缓2型糖尿病发生风险的人的2型糖尿病及其相关并发症的胰岛素促分泌剂
7. Oral Insulin Secretagogues, Insulin, and Cancer Risk in Type 2 Diabetes Mellitus [O] . Chia-Hsuin Chang, Jou-Wei Lin, Li-Chiu Wu, 2012

机译：口服胰岛素促分泌术，胰岛素和2型糖尿病的癌症风险

Oral Insulin Secretagogues, Insulin, and Cancer Risk in Type 2 Diabetes Mellitus

摘要

著录项

相似文献

相关主题

期刊订阅